Novo Nordisk's $3.1 billion Ablynx bid rejected by Belgian biotech

COPENHAGEN/BRUSSELS (Reuters) - Denmark's Novo Nordisk, the world's biggest maker of insulin, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday as it seeks to bolster its treatments for rare blood disorders.